Cargando…
Exploring new pathways in endocrine-resistant breast cancer
The most common breast cancer (BC) subtypes are hormone-dependent, being either estrogen receptor-positive (ER(+)), progesterone receptor-positive (PR(+)), or both, and altogether comprise the luminal subtype. The mainstay of treatment for luminal BC is endocrine therapy (ET), which includes several...
Autores principales: | de Pinho, Inês Soares, Abreu, Catarina, Gomes, Inês, Casimiro, Sandra, Pacheco, Teresa Raquel, de Sousa, Rita Teixeira, Costa, Luís |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400750/ https://www.ncbi.nlm.nih.gov/pubmed/36045911 http://dx.doi.org/10.37349/etat.2022.00086 |
Ejemplares similares
-
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
por: Gomes, Inês, et al.
Publicado: (2023) -
Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
por: Gomes, Inês, et al.
Publicado: (2023) -
The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
por: Ferreira, Arlindo, et al.
Publicado: (2016) -
Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases
por: Mansinho, André, et al.
Publicado: (2019) -
The Roadmap of RANKL/RANK Pathway in Cancer
por: Casimiro, Sandra, et al.
Publicado: (2021)